Market Spotlight: Idiopathic pulmonary fibrosis (IPF)


Report
41 Pages
May 2021
Region: Global
Citeline
ID: 4846087

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2019, there were 187,040 incident cases and 714,260 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 209,960 incident cases and 798,760 prevalent cases by 2028.
Roche’s Esbriet and Boehringer Ingelheim's Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I. Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route.
High-impact upcoming events in the IPF space comprise topline Phase IIa trial results for PLN-74809, topline Phase IIb trial results for GB0139, topline Phase II trial results for BLD-0409, and topline Phase III trial results for pamrevlumab.
The overall likelihood of approval of a Phase I respiratory-other asset is 4.8%, and the average probability a drug advances from Phase III is 38.5%. Drugs, on average, take 12.8 years from Phase I to approval, compared to 9.8 years in the overall respiratory space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 20 trials.
Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, closely followed by Boehringer Ingelheim.

OVERVIEWKEY TAKEAWAYS

DISEASE BACKGROUND

Disease definition
Patient segmentation
Symptoms
Risk factors
Diagnosis

TREATMENT

Pharmacologic treatment
Non-pharmacologic treatments

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

GLPG1690 for IPF (February 10, 2021)
GLPG1205 for IPF (December 1, 2020)

KEY UPCOMING EVENTSPROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Lassen, Cedars-Sinai Investigate Role Of IL-11 In Lung Fibrosis
Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
Bridge, LegoChem Team To Speed Development Of Autotaxin Inhibitor
Galapagos Teams With Poland’s OncoArendi On IPF Candidate
Boehringer, Bridge IPF Deal Collapses On Toxicity Concerns
Reborn Redx Inks Global Licensing Deal With AstraZeneca
Galapagos Seeks IPF Discovery Leads From E-Therapeutics

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHYAPPENDIX

LIST OF FIGURES

Figure 1: Trends in incident cases of IPF, 2019–28
Figure 2: Trends in prevalent cases of IPF, 2019–28
Figure 3: Overview of pipeline drugs for IPF in the US
Figure 4: Pipeline drugs for IPF, by company
Figure 5: Pipeline drugs for IPF, by drug type
Figure 6: Pipeline drugs for IPF, by classification
Figure 7: GLPG1205 for IPF (December 1, 2020): Phase II - PINTA
Figure 8: Key upcoming events in IPF
Figure 9: Probability of success in the respiratory-other pipeline
Figure 10: Clinical trials in IPF
Figure 11: Top 10 drugs for clinical trials in IPF
Figure 12: Top 10 companies for clinical trials in IPF
Figure 13: Trial locations in IPF
Figure 14: IPF trials status
Figure 15: IPF trials sponsors, by phase

LIST OF TABLES

Table 1: Incident cases of IPF, 2019–28
Table 2: Prevalent cases of IPF, 2019–28
Table 3: Marketed drugs for IPF
Table 4: Pipeline drugs for IPF in the US
Table 5: GLPG1690 for IPF (February 10, 2021)
Table 6: GLPG1205 for IPF (December 1, 2020)
Table 7: Historical global sales, by drug ($m), 2016–20
Table 8: Forecasted global sales, by drug ($m), 2021–25

Table of Contents

Related Topics

Related Reports

Global Idiopathic Pulmonary Fibrosis Treatment Market Report and Forecast 2023-2031

Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Idiopathic Pulmonary Fibrosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Idiopathic Pulmonary Fibrosis Global Market Report 2024

Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update